Next Article in Journal
Economical Analysis of Different Clinical Approaches in Pre-Viability Amniorrhexis—A Case Series
Next Article in Special Issue
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives
Previous Article in Journal
Repeat Lumbar Puncture: CSF Lactic Acid Levels are Predictive of Cure with Acute Bacterial Meningitis
Previous Article in Special Issue
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2014, 3(1), 1-24; doi:10.3390/jcm3010001

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice

1
Department of Medical Oncology, Royal North Shore Hospital, St. Leonards NSW 2065, Sydney, Australia
2
Sydney Medical School, University of Sydney, Camperdown NSW 2050, Sydney, Australia
3
Department of Medical Oncology, Gosford Hospital, Gosford NSW 2250, Australia
*
Author to whom correspondence should be addressed.
Received: 9 November 2013 / Revised: 11 December 2013 / Accepted: 16 December 2013 / Published: 9 January 2014
(This article belongs to the Special Issue Prevention and Treatment of Bone Metastases from Breast Cancer)
View Full-Text   |   Download PDF [732 KB, uploaded 9 January 2014]   |  

Abstract

Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer are associated with skeletal-related events (SREs) including pathological fractures, spinal cord compression, surgery and radiotherapy to bone, as well as bone pain and hypercalcemia, leading to impaired mobility and reduced quality of life. Greater understanding of the pathophysiology of bone metastases has led to the discovery and clinical utility of bone-targeted agents such as bisphosphonates and the receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, denosumab. Both are now a routine part of the treatment of breast cancer bone metastases to reduce SREs. With regards to prevention, there is no evidence that oral bisphosphonates can prevent bone metastases in advanced breast cancer without skeletal involvement. Several phase III clinical trials have evaluated bisphosphonates as adjuvant therapy in early breast cancer to prevent bone metastases. The current published data do not support the routine use of bisphosphonates in unselected patients with early breast cancer for metastasis prevention. However, significant benefit of adjuvant bisphosphonates has been consistently observed in the postmenopausal or ovarian suppression subgroup across multiple clinical trials, which raises the hypothesis that its greatest anti-tumor effect is in a low estrogen microenvironment. An individual patient data meta-analysis will be required to confirm survival benefit in this setting. This review summarizes the key evidence for current clinical practice and future directions. View Full-Text
Keywords: breast cancer; bone metastases; bisphosphonates; denosumab; skeletal-related events; adjuvant; randomized controlled trials; meta-analysis breast cancer; bone metastases; bisphosphonates; denosumab; skeletal-related events; adjuvant; randomized controlled trials; meta-analysis
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Li, B.T.; Wong, M.H.; Pavlakis, N. Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. J. Clin. Med. 2014, 3, 1-24.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top